Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1337
Abstract: CSL112 (apolipoprotein A‐I [human]) is a novel intravenous formulation of plasma‐derived apolipoprotein A‐I (apoA‐I) that enhances cholesterol efflux capacity. Renal impairment is a common comorbidity in acute myocardial infarction patients and is associated with impaired… read more here.
Keywords: moderate renal; csl112; renal impairment; efflux capacity ... See more keywords
CSL112 ENHANCES THE ABILITY OF SERUM TO EFFLUX CHOLESTEROL IN PATIENTS WITH MODERATE RENAL IMPAIRMENT
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)33443-5
Abstract: Background: CSL112 is a novel formulation of plasma-derived apolipoprotein A-I (apoA-I) that is in development for cardiovascular (CV) event reduction following acute coronary syndrome (ACS) by enhancement of cholesterol efflux capacity (CEC). Completed clinical trials… read more here.
Keywords: csl112; csl112 enhances; ability serum; cholesterol ... See more keywords
Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13361
Abstract: CSL112 (apolipoprotein A‐I [apoA‐I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). This phase I study aimed to… read more here.
Keywords: csl112; efflux capacity; cholesterol efflux; japanese subjects ... See more keywords
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
Sign Up to like & getrecommendations! Published in 2018 at "Arteriosclerosis, Thrombosis, and Vascular Biology"
DOI: 10.1161/atvbaha.118.310538
Abstract: Objective— CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early recurrent cardiovascular events after acute myocardial infarction. Cholesterol efflux capacity (CEC) is a marker of high-density lipoprotein… read more here.
Keywords: csl112; cholesterol; disease; atherosclerotic disease ... See more keywords
CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post–Myocardial Infarction
Sign Up to like & getrecommendations! Published in 2023 at "Arteriosclerosis, Thrombosis, and Vascular Biology"
DOI: 10.1161/atvbaha.122.318243
Abstract: Background: To characterize the effects of CSL112 (human APOA1 [apolipoprotein A1]) on the APOA1 exchange rate (AER) and the relationships with specific HDL (high-density lipoprotein) subpopulations when administered in the 90-day high-risk period post–acute myocardial… read more here.
Keywords: myocardial infarction; csl112; hdl; apoa1 exchange ... See more keywords
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiovascular Pharmacology and Therapeutics"
DOI: 10.1177/10742484221121507
Abstract: Introduction: Cholesterol efflux capacity (CEC) is impaired following acute myocardial infarction (AMI). CSL112 is an intravenous preparation of human plasma-derived apoA-I formulated with phosphatidylcholine (PC). CSL112 is intended to improve CEC and thereby prevent early… read more here.
Keywords: csl112; apoa; plasma; cholesterol efflux ... See more keywords